[ad_1]
A protein-secreting device implanted in the hippocampus of epileptic rats reduces seizures by 93% in three months, according to a preclinical study published in JNeurosci. These findings support the ongoing development of this technology and its potential translation into a new treatment for epilepsy.
Giovanna Paolone and her colleagues at the University of Ferrara, Italy, and Gloriana Therapeutics, Inc. (Providence, RI), motivated by an unmet need for effective and well-tolerated epilepsy treatments, studied the effects of gloriana targeted cell delivery system for glial cells. Neurotrophic factor derived from a lineage (GDNF) – a protein suggested by a recent study could help suppress epileptic activity.
In addition to rapidly and progressively reducing seizures in male rats – by 75% in less than two weeks – the researchers found that their device improved the anxiety-like symptoms of the rats and their performance at the time of treatment. an object recognition task, indicating an improvement in cognition.
The treatment also corrected anomalies of cerebral anatomy badociated with epilepsy. These effects persisted even after the removal of the device, indicating that this approach could alter the progression of the disease.
Adenosine reduces seizures and progression of epilepsy
Targeted long-term delivery of GDNF from encapsulated cells is neuroprotective and reduces seizures, JNeurosci (2019). DOI: 10.1523 / JNEUROSCI.0435-18.2018
Provided by
Society of Neurosciences
Quote:
Implantable device limits seizures and improves cognition in epileptic rats (January 21, 2019)
recovered on January 21, 2019
on https://medicalxpress.com/news/2019-01-implantable-device-curbs-seizures-cognition.html
This document is subject to copyright. Apart from any fair use for the purposes of studies or private research, no
part may be reproduced without written permission. Content is provided for information only.
[ad_2]
Source link